ClinicalTrials.gg
Active, not recruitingNCT05389319Updated Jun 15, 2026

A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults

A Phase 1 interventional study of Prime-2-CoV_Beta in COVID-19, sponsored by University Hospital Tuebingen. Active, not recruiting at 2 sites in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by University Hospital Tuebingen · Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
96
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in COVID-19 by University Hospital Tuebingen — 1 open to participants now, 2 under way, none of them phase 3. COVID-19 · University Hospital Tuebingen.

Planned enrollment
4th of 10
96 · median 38
Started
2022
with 1 other
Phase 1
2 of 15
none open now
Registered
15th of 15
by date

Among the 15 studies in COVID-19 by University Hospital Tuebingen, this one is the 4th largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 1, and was the 15th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

1 of the 15 studies in COVID-19 by University Hospital Tuebingen is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in COVID-19 by University Hospital Tuebingen, or all of them as a file.
02

Study summary

This is an open-label, first-in-human, dose-finding study to evaluate the safety and immunogenicity of a booster vaccination of Prime-2-CoV_Beta in healthy participants.

Read the detailed description

Eligible participants will undergo baseline assessments and will receive 1 injection of Prime-2-CoV_Beta at Day 1. Participants will be followed up through 6 months post-booster vaccination. Follow-up visits will be performed at Days 4, 8, 15, 29, and Months 3 and 6, to assess the safety, tolerability, and immunogenicity of Prime-2-CoV_Beta. Additional safety and tolerability data will be assessed 1 day and 2 days after booster vaccination (Days 2 and 3) by telephone. Initially, a total of 60 participants were planned to be vaccinated in 5 cohorts of 12 participants each. Dose ranging of Prime-2-CoV_Beta was planned to be done by dose escalation with doses ranging from 3x104 plaque forming units (PFUs) up to 3x10\^7 PFUs.

With protocol Version 7.0, Cohort 6 with 12 participants was added with 6x10\^7 PFU. With protocol Version 8.0, 1 additional cohort, Cohort 7 (1.2x10\^8 PFU, stratified by previous COVID-19 vaccinations and previous SARS-CoV-2 infections) with 24 participants will be added (total number thus 96 participants).

Procedures for Cohorts 6 and 7 will be the same as for Cohorts 1 - 5, except that for some participants in Cohort 7 ORFV shedding in urine, saliva, blood, and stool will be evaluated.

03

Conditions studied

  • COVID-19

Browse trials for

Keywords

  • COVID-19
  • vaccine
  • Orf virus
  • SARS-CoV-2
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria

  1. Healthy adult men or women aged 18 to 55 years
  2. Previous COVID-19 vaccination and previous SARS-CoV-2 infection as follows:

    1. Cohorts 1 to 7a: Full course of vaccination e.g., having received at least 3 doses of a licensed mRNA COVID-19 vaccine or having received at least 2 doses of a licensed mRNA COVID-19 vaccine and a prior SARS-CoV-2 infection, with the last dose of the vaccine being administered ≥ 10 weeks before Day 1 as documented in a respective vaccination certificate
    2. Cohort 7b: No more than 2 doses of any licensed COVID-19 vaccine. Those with fewer COVID-19 vaccinations, preferably none or just one, will be given preference. Non-mRNA COVID-19 vaccines are acceptable. The last vaccine dose must have been given ≥ 10 weeks before Day 1 as documented in a respective vaccination certificate
  3. Able to understand the participant information and providing written
  4. of 18.5 to 30.0 kg/m² and weight > 50 kg at Screening
  5. Women of must:

    1. have a negative pregnancy test at Screening (blood) and at Day 1 (urine)
    2. agree to use, and be able to comply with, highly effective measures of without interruption, from 14 days before Prime-2-CoV_Beta booster vaccination until the end of the study.

    A highly effective method of contraception or birth control (failure rate less than 1% per year when used consistently and correctly) for this study: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal, injectable), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), intrauterine device, intrauterine hormone-releasing system, bilateral tubal occlusion, sexual abstinence or vasectomized sexual partner. Abstinence is only acceptable as true abstinence when this is in line with the preferred and usual lifestyle of the participant (abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods and withdrawal] are not acceptable methods of contraception.) (no menses for at least 1 year without alternative medical cause) or surgically sterile women (tubal ligation, hysterectomy or bilateral oophorectomy) may be enrolled.

  6. Male participants must agree not to intend to father a child or to donate sperm starting at Screening, throughout the clinical study. Male participants must also

    1. abstain from sexual intercourse with a female partner (acceptable only if it is the participant's usual form of birth control/lifestyle choice: abstinent on a long-term and persistent basis). The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the participant or
    2. use adequate barrier contraception (male condom) during treatment with the product until the end of the study, and
    3. ensure that, if they have a female partner of childbearing potential, the partner uses a highly effective contraceptive method as outlined in inclusion criterion number 5
    4. use condoms during the entire study if they have a pregnant partner, to avoid exposure of the fetus to the investigational product
  7. Willing and able to comply with all study procedures based on the investigator's judgment

Exclusion Criteria:

Previous and concomitant therapy:

  1. Receipt of any vaccine (licensed or investigational) from 4 weeks before Prime-2-CoV_Beta booster vaccination or anticipated vaccination during the study until 6 weeks after the Prime-2-CoV_Beta booster vaccination
  2. Previous vaccination against COVID-19 with vaccines (licensed or investigational) other than mRNA-based vaccines (licensed or investigational) only applicable for Cohorts 1 to 7a
  3. Current or previous treatment with another investigational drug and/or medical device (within 30 days of enrollment or 5 half-lives of that investigational drug)
  4. Administration of immunoglobulins or any blood products within 2 months of Prime-2-CoV_Beta booster vaccination
  5. Chronic administration of medication associated with impaired immune responsiveness as judged by the investigator (including, but not limited to: therapy, systemic exceeding 10 mg/day of prednisone equivalent, allergy shots for hypo-sensitization, immunoglobulin, interferon, immunomodulators, cytotoxic drugs, or other similar or toxic drugs) within 2 months before the Prime-2-CoV_Beta booster vaccination (Day 1). Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.

    Previous and concomitant medical condition:

  6. Active SARS-CoV-2 infection, confirmed by a commercially available SARS-CoV-2 rapid antigen test at Day 1, or currently on quarantine
  7. {deleted}
  8. Known history of severe adverse reactions to any vaccine and/or severe allergic reactions to any component of the study vaccine, to any drug, or to any other exposure
  9. Known history of angioedema
  10. Pregnant or lactating women
  11. Any confirmed or suspected immunosuppressive or immunodeficient condition
  12. Known history of Guillain-Barré Syndrome
  13. Known infection with , virus or virus
  14. Active cancer () within 5 years before Day 1 (except for adequately treated non-melanomatous skin carcinoma, at the discretion of the investigator)
  15. Moderate or severe illness and/or fever > 38.0 °C within 1 week before Prime-2-CoV_Beta booster vaccination
  16. Any health problem (medical history and physical examination) or clinically significantly abnormal finding in biochemistry and/or hematology blood tests, urinalysis, or at Screening according to the investigator's opinion
  17. Current or history of cardiovascular disease or structural cardiac disease (including chronic or congenital heart conditions, such as chronic hypertension, coronary heart disease, myocardial infarction and arrhythmias, hypertrophic cardiomyopathy, as well as a history of myocarditis after mRNA vaccinations)
  18. History of mRNA vaccination-associated adverse events that were in nature and severity beyond the common AEs expected
  19. Current or history of gastrointestinal disease, liver disease, renal disease or endocrine disorders, (including diabetes) and neurological illness (excluding migraine), when judged as clinically significant according to the investigator's opinion
  20. Current or history of chronic respiratory diseases, including mild asthma treated by on-demand medication (resolved childhood asthma is allowed)
  21. Current or history of alcohol and/or drug abuse within the last 6 months before Day 1

    Previous and concomitant clinical study experience

  22. Current participation in another study or previous enrollment in this clinical study

    Other exclusion criteria

  23. Investigator or employee of the study group or sponsor with direct involvement in the proposed study or relatives of the research staff with direct involvement in the proposed study
  24. Prolonged exposure to sheep or goats (e.g., shepherds, sheep farmer)
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Prime-2-CoV\_Beta, dose: 30 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 2

    Prime-2-CoV\_Beta, dose: 300 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 3

    Prime-2-CoV\_Beta, dose: 3 000 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 4

    Prime-2-CoV\_Beta, dose: 150 000 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 5

    Prime-2-CoV\_Beta, dose: 30 000 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 6

    Prime-2-CoV\_Beta, dose: 60 000 000 PFUs

    Biological: Prime-2-CoV_Beta

  • Experimental
    Cohort 7

    Prime-2-CoV\_Beta, dose: 1 200 000 000 PFUs

    Biological: Prime-2-CoV_Beta

Interventions

  • BiologicalPrime-2-CoV_Beta

    1 intramuscular injection (1.0 mL each) into the deltoid muscle on Day 1

06

What researchers measure

Primary outcomes

  1. Proportion of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) throughout the study

    All safety data will be summarized descriptively overall and by cohort. TEAEs will be summarized by descriptive statistics using contingency tables (counts of events, number and proportion of participants with events) and presented by system organ class and preferred term, as well as by severity.

    Time frame: Day 1 (vaccination day) to month 6 (end of study visit, ±14 days)

  2. Proportion of participants with solicited local adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): pain at injection site, redness, induration, and swelling.

    Solicited local adverse events will be summarized by descriptive statistics using contingency tables (counts of events, number and proportion of participants with events).

    Time frame: Day 1 (vaccination day) to day 8 (Visit 3; ±1 day)

  3. Proportion of participants with solicited systemic adverse events (first 7 days after Prime-2-CoV_Beta booster vaccination): fever, fatigue, headache, chills, vomiting, nausea, diarrhea, new or worsened muscle pain, new or worsened joint pain.

    Solicited systemic adverse events will be summarized by descriptive statistics using contingency tables (counts of events, number and proportion of participants with events).

    Time frame: Day 1 (vaccination day) to day 8 (Visit 3; ±1 day)

  4. Proportion of participants with unsolicited treatment-emergent adverse events throughout the study

    All unsolicited adverse events which occur after the first administration of investigational product are defined as treatment-emergent adverse events. Treatment-emergent adverse events will be summarized by descriptive statistics using contingency tables (counts of events, number and proportion of participants with events) and presented by system organ class and preferred term, as well as by severity.

    Time frame: Day 1 (vaccination day) to month 6 (end of study visit, ±14 days)

Secondary outcomes

  1. Level of neutralizing antibody titers versus SARS CoV-2 (Wuhan wild type) at each post-booster vaccination assessment

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  2. Geometric mean fold rise (GMFR) of neutralizing antibodies (versus Wuhan wild type) from Baseline to each post-booster vaccination assessment

    The fold change from Baseline will be computed for each participant. The fold rise is calculated as the ratio of the post- vs pre-vaccination titer value. The fold change from Baseline will be summarized using descriptive statistics by cohort and visit. Additionally, the GMFR with 95% CI will be presented.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  3. IgG antibody titer versus SARS-CoV-2 receptor-binding protein

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  4. Geometric mean titers (GMT) of receptor-binding protein-specific IgG antibodies

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  5. Geometric mean fold rise of receptor-binding protein-specific IgG antibodies from Baseline

    The fold change from Baseline will be computed for each participant. The fold rise is calculated as the ratio of the post- vs pre-vaccination titer value. The fold change from Baseline will be summarized using descriptive statistics by cohort and visit. Additionally, the geometric mean fold rise with 95% confidence interval will be presented.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  6. Proportion of participants with adverse events of special interest throughout the study

    Adverse events of special interest will be summarized by descriptive statistics using contingency tables (counts of events,number and proportion of participants with events) and presented by system organ class and preferred term, as well as by severity. The frequency (% of participants) of adverse events of special interest throughout the study will be tabulated.

    Time frame: Day 1 (vaccination day) to day 8 (Visit 3; ±1 day)

Other outcomes

  1. IgG antibody titer versus SARS-CoV-2 S1 protein

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  2. Geometric mean titers of IgG S1-specific antibodies

    Absolute values of serological immunogenicity assays as described will be presented using descriptive summary statistics by cohort and visit. Additionally, Geometric mean titers with 95% confidence interval (CI) will be provided. For each cohort, serological immunogenicity assays will be presented graphically displaying Geometric mean titers with 95% CIs at all visits.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  3. Geometric mean fold rise of IgG S1-specific antibodies from Baseline

    The fold change from Baseline will be computed for each participant. The fold rise is calculated as the ratio of the post- vs pre-vaccination titer value. The fold change from Baseline will be summarized using descriptive statistics by cohort and visit. Additionally, the geometric mean fold rise with 95% CI will be presented.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  4. IgG antibody titer versus SARS-CoV-2 N-protein

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  5. Geometric mean titers of N-specific IgG antibodies

    Absolute values of serological immunogenicity assays as described will be presented using descriptive summary statistics by cohort and visit. Additionally, geometric mean titers with 95% confidence interval (CI) will be provided. For each cohort, serological immunogenicity assays will be presented graphically displaying geometric mean titers with 95% CIs at all visits.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  6. Geometric mean fold rise of N-specific IgG antibodies from Baseline

    The fold change from Baseline will be computed for each participant. The fold rise is calculated as the ratio of the post- vs pre-vaccination titer value. The fold change from Baseline will be summarized using descriptive statistics by cohort and visit. Additionally, the geometric mean fold rise with 95% confidence intervals will be presented.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  7. Level of neutralizing antibody titers versus the variant of concern SARS-CoV-2_Beta, SARS-CoV-2_Delta and SARS-CoV-2_Omicron at each post-booster vaccination assessment

    Immunogenicity endpoints will be descriptively analyzed by cohort and visit. Separate analyses will be done for the different parameters, e.g., different antibodies evaluated with different serological immunogenicity assays.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  8. Geometric mean fold rise of neutralizing antibodies from Baseline to each post-booster vaccination assessment

    The fold change from Baseline will be computed for each participant. The fold rise is calculated as the ratio of the post- vs pre-vaccination titer value. The fold change from Baseline will be summarized using descriptive statistics by cohort and visit. Additionally, the geometric mean fold rise with 95% confidence intervals will be presented.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 3 (±14 days), month 6 (end of study visit, ±14 days)

  9. Percentage of cytokine producing S and N protein-specific T-cells compared to Baseline

    Analyses based on S- and N-specific antibodies will be performed as described for receptor-binding protein specific antibodies.

    Time frame: Day 1 (vaccination day), day 8 (±1 day), day 15 (±2 days), day 29 (±1 day), month 6 (end of study visit, ±14 days)

  10. Additional assays to measure the immune response to Prime-2-CoV_Beta and the immune response to the Orf virus vector backbone

    Orf virus-specific antibodies will be summarized descriptively as described for virus-specific antibodies.

    Time frame: Day 1 (vaccination day), day 15 (±2 days), day 29 (±1 day), month 6 (end of study visit, ±14 days)

  11. Additional assays to measure ORF virus (ORFV) shedding in urine, saliva, blood, and stool

    ORFV shedding will be assessed with quantitative polymerase chain reaction to allow detection of genome copies of ORFV.

    Time frame: Day 1 (vaccination day), day 2, day 4, day 8 (±1 day)

07

Study locations

2 sites
  • University Hospital Tübingen, Institute of Tropical Medicine
    Tübingen, Baden-Wurttemberg 72074, Germany
  • Bernhard-Nocht-Institut für Tropenmedizin
    Hamburg, Free and Hanseatic City of Hamburg 20359, Germany
08

References and documents

Publications

  • Esen M, Fischer-Herr J, Gabor JJ, Gaile JM, Fleischmann WA, Smeenk GW, de Moraes RA, Belard S, Calle CL, Woldearegai TG, Egger-Adam D, Haug V, Metz C, Reguzova A, Loffler MW, Balode B, Matthies LC, Ramharter M, Amann R, Kremsner PG. First-in-Human Phase I Trial to Assess the Safety and Immunogenicity of an Orf Virus-Based COVID-19 Vaccine Booster. Vaccines (Basel). 2024 Nov 18;12(11):1288. doi: 10.3390/vaccines12111288. PubMed 39591190 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2026, 54 months after the start.

Of 151 non-industry phase 1 interventional studies under COVID-19, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's planned 54 months is above that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2022
First posted
May 25, 2022
StartActual
Jun 24, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05389319
Collaborators
FGK Clinical Research GmbH, VisMederi srl, Staburo GmbH, Viedoc Technologies AB
Responsible party
Sponsor
First posted
May 25, 2022
Start date
Jun 24, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jun 15, 2026

Study contacts

Meral Esen, Dr.
principal investigator · University Hospital Tübingen, Institute of Tropical Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion